Cargando…

Overexpressed vs mutated Kras in murine fibroblasts: a molecular phenotyping study

Ras acts in signalling pathways regulating the activity of multiple cellular functions including cell proliferation, differentiation, and apoptosis. Amino-acid exchanges at position 12, 13, or 61 of the Kras gene convert the proto-oncogene into an activated oncogene. Until now, a direct comparison o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Horsch, M, Recktenwald, C V, Schädler, S, Hrabé de Angelis, M, Seliger, B, Beckers, J
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2009
Materias:	Molecular Diagnostics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2653730/ https://www.ncbi.nlm.nih.gov/pubmed/19190631 http://dx.doi.org/10.1038/sj.bjc.6604882

Ejemplares similares

RAD21 cohesin overexpression is a prognostic and predictive marker exacerbating poor prognosis in KRAS mutant colorectal carcinomas
por: Deb, S, et al.
Publicado: (2014)

KRAS mutations detected by the amplification refractory mutation system–Scorpion assays strongly correlate with therapeutic effect of cetuximab
por: Bando, H, et al.
Publicado: (2011)

KRAS mutations in primary tumours and post-FOLFOX metastatic lesions in cases of colorectal cancer
por: Kawamoto, Y, et al.
Publicado: (2012)

Triple negative breast carcinoma EGFR amplification is not associated with EGFR, Kras or ALK mutations
por: Secq, V, et al.
Publicado: (2014)

Clinicopathological and prognostic significance of interleukin-8 expression and its relationship to KRAS mutation in lung adenocarcinoma
por: Sunaga, N, et al.
Publicado: (2014)

A comparison of three methods for detecting KRAS mutations in formalin-fixed colorectal cancer specimens
por: Gonzalez de Castro, D, et al.
Publicado: (2012)

KRAS mutation detection and prognostic potential in sporadic colorectal cancer using high-resolution melting analysis
por: Deschoolmeester, V, et al.
Publicado: (2010)

KRAS and BRAF mutations are prognostic biomarkers in patients undergoing lung metastasectomy of colorectal cancer
por: Renaud, S, et al.
Publicado: (2015)

KRAS-mutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer
por: Spindler, K G, et al.
Publicado: (2013)

KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients
por: Knijn, N, et al.
Publicado: (2011)

KRAS mutational subtype and copy number predict in vitro response of human pancreatic cancer cell lines to MEK inhibition
por: Hamidi, H, et al.
Publicado: (2014)

KRAS, NRAS, BRAF mutation comparison of endoscopic and surgically removed primary CRC paired samples: is endoscopy biopsy material adequate for molecular evaluation?
por: Saridaki, Z, et al.
Publicado: (2015)

Prognostic value of the KRAS G12V mutation in 841 surgically resected Caucasian lung adenocarcinoma cases
por: Renaud, Stéphane, et al.
Publicado: (2015)

Specific mutations in KRAS codon 12 are associated with worse overall survival in patients with advanced and recurrent colorectal cancer
por: Jones, Robert P, et al.
Publicado: (2017)

Extreme assay sensitivity in molecular diagnostics further unveils intratumour heterogeneity in metastatic colorectal cancer as well as artifactual low-frequency mutations in the KRAS gene
por: Mariani, Sara, et al.
Publicado: (2017)

Unique volatolomic signatures of TP53 and KRAS in lung cells
por: Davies, M P A, et al.
Publicado: (2014)

KRAS mutational status affects oxaliplatin-based chemotherapy independently from basal mRNA ERCC-1 expression in metastatic colorectal cancer patients
por: Basso, M, et al.
Publicado: (2013)

Overexpression of nucleostemin contributes to an advanced malignant phenotype and a poor prognosis in oral squamous cell carcinoma
por: Yoshida, R, et al.
Publicado: (2014)

Prognostic role of EGFR gene copy number and KRAS mutation in patients with locally advanced rectal cancer treated with preoperative chemoradiotherapy
por: Bengala, C, et al.
Publicado: (2010)

Overexpression of E2F-5 correlates with a pathological basal phenotype and a worse clinical outcome
por: Umemura, S, et al.
Publicado: (2009)

The prognostic role of KRAS, BRAF, PIK3CA and PTEN in colorectal cancer
por: Eklöf, V, et al.
Publicado: (2013)

Specific KRAS amino acid substitutions and EGFR mutations predict site-specific recurrence and metastasis following non-small-cell lung cancer surgery
por: Renaud, Stéphane, et al.
Publicado: (2016)

KRAS and BRAF mutations are rare and related to DNA mismatch repair deficiency in gastric cancer from the East and the West: Results from a large international multicentre study
por: van Grieken, N C T, et al.
Publicado: (2013)

P4H9-detected molecule expression on spindle-shaped fibroblasts indicates malignant phenotype of colorectal cancer
por: Yokoyama, Shozo, et al.
Publicado: (2015)

Tumour gene expression predicts response to cetuximab in patients with KRAS wild-type metastatic colorectal cancer
por: Baker, J B, et al.
Publicado: (2011)

Down-regulation of KRAS-interacting miRNA-143 predicts poor prognosis but not response to EGFR-targeted agents in colorectal cancer
por: Pichler, M, et al.
Publicado: (2012)

Prognostic significance of overexpression of c-Met oncoprotein in cholangiocarcinoma
por: Miyamoto, M, et al.
Publicado: (2011)

Molecular characteristics of screen-detected vs symptomatic breast cancers and their impact on survival
por: Dawson, S J, et al.
Publicado: (2009)

Overexpression and altered glycosylation of MUC1 in malignant mesothelioma
por: Creaney, J, et al.
Publicado: (2008)

Periostin is frequently overexpressed and enhances invasion and angiogenesis in oral cancer
por: Siriwardena, B S M S, et al.
Publicado: (2006)

DKC1 overexpression associated with prostate cancer progression
por: Sieron, P, et al.
Publicado: (2009)

Overexpression of connexin 43 reduces melanoma proliferative and metastatic capacity
por: Tittarelli, A, et al.
Publicado: (2015)

Cellular and molecular phenotypes of proliferating stromal cells from human carcinomas
por: Kopantzev, E P, et al.
Publicado: (2010)

Overexpression of SMYD2 contributes to malignant outcome in gastric cancer
por: Komatsu, S, et al.
Publicado: (2015)

Clinical significance of CD151 overexpression in subtypes of invasive breast cancer
por: Kwon, M J, et al.
Publicado: (2012)

Overexpression of podocalyxin-like protein is an independent factor of poor prognosis in colorectal cancer
por: Larsson, A, et al.
Publicado: (2011)

Cdc20 and securin overexpression predict short-term breast cancer survival
por: Karra, H, et al.
Publicado: (2014)

OPN/CD44v6 overexpression in laryngeal dysplasia and correlation with clinical outcome
por: Staibano, S, et al.
Publicado: (2007)

UbcH10 overexpression may represent a marker of anaplastic thyroid carcinomas
por: Pallante, P, et al.
Publicado: (2005)

A modified Trastuzumab antibody for the immunohistochemical detection of HER-2 overexpression in breast cancer
por: Bussolati, G, et al.
Publicado: (2005)

Cannot write session to /tmp/vufind_sessions/sess_h381ak8ejvl4earg0edfr2af7g